TELOMIR PHARMACEUTICALS INC

Company Overview

Telomir Pharmaceuticals Inc. is a development‑stage biotechnology company focused on telomere/telomerase‑related therapeutics and antimicrobial candidates. Recent preclinical progress centers on Telomir‑1 (programs targeting age‑related macular degeneration, Werner Syndrome, Wilson’s disease, HGPS, and epigenetic effects in a prostate cancer xenograft) and identification of Telomir‑Ag2, a stabilized Ag(II) antimicrobial candidate. Financially the company is loss‑making and cash‑constrained (Q2 2025 loss $5.1M; cash and equivalents $0.8M at quarter end), with management warning of substantial doubt about going concern absent additional financing. Near‑term value drivers are continued preclinical milestones, advancement toward IND/clinical trials, and successful capital raises.

Executive Compensation Practices

Telomir’s reported compensation profile shows heavy reliance on equity‑based awards: $6.0M of stock‑based compensation drove a large portion of H1 2025 G&A expense, indicating executives and staff are paid materially in equity rather than cash. This aligns with common Biotechnology sector practice—lower cash salaries augmented by options/restricted stock and milestone‑linked grants tied to R&D progress (preclinical milestones, IND filing, or financing events). Because R&D activity and cash runway are the primary operational constraints, compensation committees are likely to emphasize retention via time‑vesting awards and milestone bonuses that preserve cash while aligning pay with development milestones. Investors should watch for large non‑cash awards that can spike reported G&A and for any related‑party arrangements (affiliated Bayshore Trust financing) that could influence the structure or timing of awards to insiders.

Insider Trading Considerations

Given the company’s small cash runway and reliance on equity financings (recent $3.0M restricted investment from an affiliate, an ATM block sale and an available $5.0M facility), insider transactions will often cluster around financing events, option exercises for tax payments, and post‑milestone liquidity moves. Material preclinical results, IND progress, or financing news are likely to be treated as material nonpublic information—insiders should observe standard blackout windows and may use 10b5‑1 plans; traders should monitor Form 4 filings closely for timing relative to press releases and ATM offerings. Additionally, related‑party investments (Bayshore Trust) raise the need to scrutinize disclosures for potential conflicts or preferential access to shares; Section 16 reporting and disclosure of related‑party transactions are important filters when interpreting insider activity.